Also Read: How To Invest In Startups
4. Minerva Neurosciences Inc (NASDAQ:NERV): Shares of the company closed 39% lower on Wednesday but has gained 4.2% in extended trading. Minerva said in a statement the FDA has confirmed it will not file the company’s new drug application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
Read Next: This Tesla Model Could Be The Bestselling Vehicle Of 2023 And Not Just For EVs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
